Disruptive innovation to combat antimicrobial resistance
Procarta Biosystems Ltd aims to revolutionise the treatment of serious and life-threatening infection through the development of innovative new oligonucleotide-based antimicrobials. Our goal is to radically improve patient well-being and aid in the global fight against AMR.
The world is running out of antimicrobial medicines. Antimicrobial resistance (AMR) is one of the most serious global healthcare threats affecting all ages and populations.
We are developing novel medicines that are active against resistant bacterial strains, have a controllable microbiological spectrum and are designed by a rapid and rational process.
We are a passionate and skilled drug discovery and development biotech team developing an innovative new class of oligonucleotide antimicrobial agents.